Comparison of the risks of combustible cigarettes, e-cigarettes, and heated tobacco products
Article information
J Korean Med Assoc. 2020;63(2):96-104
Publication date (electronic) : 2020 February 15
doi :
https://doi.org/10.5124/jkma.2020.63.2.96
Received 2020 January 06; Accepted 2020 January 30.
Abstract
E-cigarettes (ECs) and heated tobacco products (HTPs) have become popular in Korea; hence, it is important to determine whether ECs and HTPs are less hazardous than combustible cigarettes (CCs). In general, the levels of harmful and potentially harmful constituents (HPHCs) are lower in ECs and HTPs than in CCs, although the levels of some heavy metals and HPHCs are higher in ECs and HTPs than in CCs. ECs and HTPs showed possible adverse effects on respiratory and cardiovascular system function, which could result in chronic respiratory and cardiovascular system diseases in animals. An analysis of biomarkers showed that ECs had possible adverse health effects on the respiratory and cardiovascular systems, in addition the effects of HTP on respiratory and cardiovascular systems were not significantly different than those of CC. Epidemiological studies identified positive associations between EC use and asthma, chronic obstructive pulmonary disease, and myocardial infarction. Only one epidemiologic study reported a positive association between ever using HTPs and asthma, allergic rhinitis, and atopic dermatitis among adolescents. Modelling studies of ECs did not show consistent findings regarding the health effects compared with those of CCs. A modeling study of HTPs, performed by tobacco industry, has been criticized for many unfounded assumptions. Lower levels of HPHCs in ECs and HTPs, compared with those in CCs, cannot be directly translated into health benefits because the relationship between exposure and effects is non-linear for cardiovascular diseases and because the duration of exposure is more important than the level of exposure in determining lung cancer mortality. In summary, there is no definite health benefit in using ECs or HTPs instead of CCs, for the individual or the population; hence, tobacco control measures should be the same for ECs, HTPs, and CCs. ECs and HTPs have become popular in Korea; hence, it is important to determine whether ECs and HTPs are less hazardous than CCs.
Notes
Conflict of Interest
No potential conflict of interest relevant to this article was reported.
References
1. Korea Centers for Disease Control and Prevention. Major findings from KNHANES (2018) and KYRBSS (2019) Cheongju: Korea Centers for Disease Control and Prevention; 2019.
2. Cho HJ, Kim HJ, Lee CM, Kim KW, Kim JY, Lee JA. Analysis on use pattern of heated tobacco products and their impact on quit smoking intention Sejong: Ministry of Health and Welfare; 2018.
3. Lee C, Kim S, Cheong YS. Issues of new types of tobacco (e-cigarette and heat-not-burn tobacco): from the perspective of ‘tobacco harm reduction’. J Korean Med Assoc 2018;61:181–190.
4. Mallock N, Pieper E, Hutzler C, Henkler-Stephani F, Luch A. Heated tobacco products: a review of current knowledge and initial assessments. Front Public Health 2019;7287.
5. National Academies of Sciences, Engineering, and Medicine. Public health consequences of e-cigarettes Washington, DC: National Academies Press; 2018.
6. Simonavicius E, McNeill A, Shahab L, Brose LS. Heat-not-burn tobacco products: a systematic literature review. Tob Control 2019;28:582–594.
7. Auer R, Concha-Lozano N, Jacot-Sadowski I, Cornuz J, Berthet A. Heat-not-burn tobacco cigarettes: smoke by any other name. JAMA Intern Med 2017;177:1050–1052.
8. St Helen G, Jacob III P, Nardone N, Benowitz NL. IQOS: examination of Philip Morris International's claim of reduced exposure. Tob Control 2018;27Suppl 1. :s30–s36.
9. Gotts JE, Jordt SE, McConnell R, Tarran R. What are the respiratory effects of e-cigarettes? BMJ 2019;366l5275.
10. Putzhammer R, Doppler C, Jakschitz T, Heinz K, Forste J, Danzl K, Messner B, Bernhard D. Vapours of US and EU market leader electronic cigarette brands and liquids are cytotoxic for human vascular endothelial cells. PLoS One 2016;11e0157337.
11. Moazed F, Chun L, Matthay MA, Calfee CS, Gotts J. Assessment of industry data on pulmonary and immunosuppressive effects of IQOS. Tob Control 2018;27Suppl 1. :s20–s25.
12. Leigh NJ, Tran PL, O'Connor RJ, Goniewicz ML. Cytotoxic effects of heated tobacco products (HTP) on human bronchial epithelial cells. Tob Control 2018;27Suppl 1. :s26–s29.
13. Nabavizadeh P, Liu J, Havel CM, Ibrahim S, Derakhshandeh R, Jacob III P, Springer ML. Vascular endothelial function is impaired by aerosol from a single IQOS HeatStick to the same extent as by cigarette smoke. Tob Control 2018;27Suppl 1. :s13–s19.
14. Goniewicz ML, Smith DM, Edwards KC, Blount BC, Caldwell KL, Feng J, Wang L, Christensen C, Ambrose B, Borek N, van Bemmel D, Konkel K, Erives G, Stanton CA, Lambert E, Kimmel HL, Hatsukami D, Hecht SS, Niaura RS, Travers M, Lawrence C, Hyland AJ. Comparison of nicotine and toxicant exposure in users of electronic cigarettes and combustible cigarettes. JAMA Netw Open 2018;1e185937.
15. Skotsimara G, Antonopoulos AS, Oikonomou E, Siasos G, Ioakeimidis N, Tsalamandris S, Charalambous G, Galiatsatos N, Vlachopoulos C, Tousoulis D. Cardiovascular effects of electronic cigarettes: a systematic review and meta-analysis. Eur J Prev Cardiol 2019;26:1219–1228.
16. Glantz SA. PMI's own in vivo clinical data on biomarkers of potential harm in Americans show that IQOS is not detectably different from conventional cigarettes. Tob Control 2018;27Suppl 1. :s9–s12.
17. Chun L, Moazed F, Matthay M, Calfee C, Gotts J. Possible hepatotoxicity of IQOS. Tob Control 2018;27Suppl 1. :s39–s40.
18. Stephens WE. Comparing the cancer potencies of emissions from vapourised nicotine products including e-cigarettes with those of tobacco smoke. Tob Control 2018;27:10–17.
19. Wang MP, Ho SY, Leung LT, Lam TH. Electronic cigarette use and respiratory symptoms in Chinese adolescents in Hong Kong. JAMA Pediatr 2016;170:89–91.
20. McConnell R, Barrington-Trimis JL, Wang K, Urman R, Hong H, Unger J, Samet J, Leventhal A, Berhane K. Electronic cigarette use and respiratory symptoms in adolescents. Am J Respir Crit Care Med 2017;195:1043–1049.
21. Cho JH, Paik SY. Association between electronic cigarette use and asthma among high school students in South Korea. PLoS One 2016;11e0151022.
22. Wills TA, Pagano I, Williams RJ, Tam EK. E-cigarette use and respiratory disorder in an adult sample. Drug Alcohol Depend 2019;194:363–370.
23. Hedman L, Backman H, Stridsman C, Bosson JA, Lundbäck M, Lindberg A, Rönmark E, Ekerljung L. Association of electronic cigarette use with smoking habits, demographic factors, and respiratory symptoms. JAMA Netw Open 2018;1e180789.
24. Bhatta DN, Glantz SA. Association of e-cigarette use with respiratory disease among adults: a longitudinal analysis. Am J Prev Med 2020;58:182–190.
25. Centers for Disease Control and Prevention. Outbreak of lung injury associated with the use of e-cigarette, or vaping, products [Internet] Atlanta: Centers for Disease Control and Prevention; 2019. cited 2019 Dec 24. Available from: https://www.cdc.gov/tobacco/basic_information/e-cigarettes/severe-lung-disease.html#latest-outbreak.
26. Landman ST, Dhaliwal I, Mackenzie CA, Martinu T, Steele A, Bosma KJ. Life-threatening bronchiolitis related to electronic cigarette use in a Canadian youth. CMAJ 2019;191:E1321–E1331.
27. Alzahrani T, Pena I, Temesgen N, Glantz SA. Association between electronic cigarette use and myocardial infarction. Am J Prev Med 2018;55:455–461.
28. Osei AD, Mirbolouk M, Orimoloye OA, Dzaye O, Uddin SMI, Benjamin EJ, Hall ME, DeFilippis AP, Stokes A, Bhatnagar A, Nasir K, Blaha MJ. Association between e-cigarette use and cardiovascular disease among never and current combustible-cigarette smokers. Am J Med 2019;132:949–954.
29. Bhatta DN, Glantz SA. Electronic cigarette use and myocardial infarction among adults in the US Population Assessment of Tobacco and Health. J Am Heart Assoc 2019;8e012317.
30. Lee A, Lee SY, Lee KS. The use of heated tobacco products is associated with asthma, allergic rhinitis, and atopic dermatitis in Korean adolescents. Sci Rep 2019;917699.
31. Levy DT, Borland R, Lindblom EN, Goniewicz ML, Meza R, Holford TR, Yuan Z, Luo Y, O'Connor RJ, Niaura R, Abrams DB. Potential deaths averted in USA by replacing cigarettes with e-cigarettes. Tob Control 2018;27:18–25.
32. Soneji SS, Sung HY, Primack BA, Pierce JP, Sargent JD. Quantifying population-level health benefits and harms of e-cigarette use in the United States. PLoS One 2018;13e0193328.
33. Kalkhoran S, Glantz SA. E-cigarettes and smoking cessation in real-world and clinical settings: a systematic review and meta-analysis. Lancet Respir Med 2016;4:116–128.
34. Berry KM, Reynolds LM, Collins JM, Siegel MB, Fetterman JL, Hamburg NM, Bhatnagar A, Benjamin EJ, Stokes A. E-cigarette initiation and associated changes in smoking cessation and reduction: the Population Assessment of Tobacco and Health Study, 2013-2015. Tob Control 2019;28:42–49.
35. Hajek P, Phillips-Waller A, Przulj D, Pesola F, Myers Smith K, Bisa lN, Li J, Parrott S, Sasieni P, Dawkins L, Ross L, Goniewicz M, Wu Q, McRobbie HJ. A randomized trial of e-cigarettes versus nicotine-replacement therapy. N Engl J Med 2019;380:629–637.
36. Soneji S, Barrington-Trimis JL, Wills TA, Leventhal AM, Unger JB, Gibson LA, Yang J, Primack BA, Andrews JA, Miech RA, Spindle TR, Dick DM, Eissenberg T, Hornik RC, Dang R, Sargent JD. Association between initial use of e-cigarettes and subsequent cigarette smoking among adolescents and young adults: a systematic review and meta-analysis. JAMA Pediatr 2017;171:788–797.
37. Max WB, Sung HY, Lightwood J, Wang Y, Yao T. Modelling the impact of a new tobacco product: review of Philip Morris International's Population Health Impact Model as applied to the IQOS heated tobacco product. Tob Control 2018;27Suppl 1. :s82–s86.
38. Lee JA, Lee S, Cho HJ. The relation between frequency of e-cigarette use and frequency and intensity of cigarette smoking among South Korean adolescents. Int J Environ Res Public Health 2017;14305.
39. Lim J, Lee JA, Fong GT, Yan M, Driezen P, Seo HG, Cho HJ. Awareness and use of e-cigarettes and vaping behaviors among Korean adult smokers: ITC 2016 Korean study. J Korean Soc Res Nicotine Tob 2018;9 Suppl 1:S11–S21.
40. Cho HJ, Kimm HJ, Lee CM, Kim KW, Kim JY, Lee JA. Analysis of heated tobacco product use and impact on smoking cessation for Korean adults Sejong: Ministry of Health and Social Affair; 2018.
41. Popova L, Lempert LK, Glantz SA. Light and mild redux: heated tobacco products' reduced exposure claims are likely to be misunderstood as reduced risk claims. Tob Control 2018;27Suppl 1. :s87–s95.
42. El-Toukhy S, Baig SA, Jeong M, Byron MJ, Ribisl KM, Brewer NT. Impact of modified risk tobacco product claims on beliefs of US adults and adolescents. Tob Control 2018;27Suppl 1. :s62–s69.
43. Glantz SA. Heated tobacco products: the example of IQOS. Tob Control 2018;27Suppl 1. :s1–s6.
44. McKelvey K, Popova L, Kim M, Chaffee BW, Vijayaraghavan M, Ling P, Halpern-Felsher B. Heated tobacco products likely appeal to adolescents and young adults. Tob Control 2018;27Suppl 1. :s41–s47.
45. Cullen KA, Gentzke AS, Sawdey MD, Chang JT, Anic GM, Wang TW, Creamer MR, Jamal A, Ambrose BK, King BA. e-cigarette use among youth in the United States, 2019. JAMA 2019;322:2095–2103.
46. Hoffmann D, Hoffmann I, El-Bayoumy K. The less harmful cigarette: a controversial issue. a tribute to Ernst L. Wynder. Chem Res Toxicol 2001;14:767–790.
47. Law MR, Wald NJ. Environmental tobacco smoke and ischemic heart disease. Prog Cardiovasc Dis 2003;46:31–38.
48. Flanders WD, Lally CA, Zhu BP, Henley SJ, Thun MJ. Lung cancer mortality in relation to age, duration of smoking, and daily cigarette consumption: results from Cancer Prevention Study II. Cancer Res 2003;63:6556–6562.
Article information Continued
© Korean Medical Association
Korean Medical Association
